Zions Bancorporation’s Array Biopharma Inc ARRY Stock Holding History

Zions Bancorporation’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,203	Closed	-$76K	–	1056
2017 Q3	$76K	Buy	+6,203	New	+$57.6K	0.01%	488

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Zions Bancorporation's ARRY Position: Q4 2017 in Review

Zions Bancorporation sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 6,203 shares — an estimated $76K sold.

Zions Bancorporation first reported a position in ARRY in Q3 2017 and held it in 1 quarter. The position peaked at $76K in Q3 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

Zions Bancorporation reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
Zions Bancorporation sold 6,203 Array Biopharma Inc shares in Q4 2017, an estimated $76K.
Zions Bancorporation first reported a position in Array Biopharma Inc in Q3 2017 and held it in 1 quarter.
Zions Bancorporation's Array Biopharma Inc position peaked at $76K in Q3 2017.
191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on Zions Bancorporation's 13F filing for Q4 2017, filed 14 Feb 2018.